Trials / Conditions / Refractory Grade 3b Follicular Lymphoma

Refractory Grade 3b Follicular Lymphoma

11 registered clinical trials studyying Refractory Grade 3b Follicular Lymphoma — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lym NCT07098364	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726	University of Washington	Phase 2
Recruiting	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373	Mayo Clinic	Phase 2
Recruiting	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049	Yazeed Sawalha	Phase 1 / Phase 2
Recruiting	Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527	AIDS Malignancy Consortium	Phase 1
Recruiting	Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymp NCT05672251	City of Hope Medical Center	Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Active Not Recruiting	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymph NCT05359211	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Withdrawn	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536	City of Hope Medical Center	Phase 1